Aurobindo receives FDA approval for dofetilide capsules
Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application for Dofetilide Capsules, 0.125 mg, 0.25 mg, and 0.5 mg. Aurobindo’s dofetilide capsules are an AB-rated generic equivalent to the reference listed drug, Pfizer’s Tikosyn.